WordNet

the 8th letter of the Roman alphabet (同)h
any of a large variety of proteins normally present in the body or produced in response to an antigen which it neutralizes, thus producing an immune response
infection by the human immunodeficiency virus

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. HIV感染に対するスクリーニングおよび診断的検査 screening and diagnostic testing for hiv infection
2. 急性期および早期のHIV感染：臨床症状および診断 acute and early hiv infection clinical manifestations and diagnosis
3. 成人におけるHIVへの非職業的曝露 nonoccupational exposure to hiv in adults
4. HIV感染関連の認知機能障害：マネージメント hiv associated neurocognitive disorders management
5. 輸血によるHIV感染およびAIDS transfusion transmitted hiv infection and aids

Pratt GW1, Fan A1, Melakeberhan B1, Klapperich CM2.
Analytica chimica acta.Anal Chim Acta.2018 Aug 9;1017:34-40. doi: 10.1016/j.aca.2018.02.039. Epub 2018 Feb 20.
PMID 29534793

Alterations in natural killer and dendritic cell subsets in individuals with HIV-associated neurotuberculosis.

Rao D1, Venkataswamy MM1, Vasanthapuram R1, Satishchandra P2, Desai A1.
Journal of medical virology.J Med Virol.2018 May;90(5):899-906. doi: 10.1002/jmv.25042. Epub 2018 Feb 15.
PMID 29396991

cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.

Dey AK1, Cupo A2, Ozorowski G3, Sharma VK1, Behrens AJ4,5, Go EP6, Ketas TJ2, Yasmeen A2, Klasse PJ2, Sayeed E1, Desaire H6, Crispin M4, Wilson IA3, Sanders RW2,7, Hassell T1, Ward AB3, Moore JP2.
Biotechnology and bioengineering.Biotechnol Bioeng.2018 Apr;115(4):885-899. doi: 10.1002/bit.26498. Epub 2017 Dec 11.
PMID 29150937

Effects of different promoters on the virulence and immunogenicity of a HIV-1 Env-expressing recombinant vaccinia vaccine

Isshiki Mao,Zhang Xianfeng,Sato Hirotaka,Ohashi Takashi,Inoue Makoto,Shida Hisatoshi
Vaccine 32(7), 839-845, 2014-02-07
… This protocol induced both humoral and cellular immune responses against the HIV-1 envelope protein. … The current study aims to optimize this regimen by comparing the immunogenicity and safety of two rm8 Delta strains that express HIV-1 Env under the control of a moderate promoter, p7.5, or a strong promoter, pSFJ1-10. … however, m8 Delta-pSFJ-JRCSFenv elicited a stronger anti-Env antibody response whereas m8 Delta-p7.5-JRCSFenv induced a stronger Env-specific cytotoxic T lymphocyte response. …
NAID 120005425328

Chronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in northern Thailand

Tsuchiya Naho,Pathipvanich Panita,Rojanawiwat Archawin,Wichukchinda Nuanjun,Koga Ichiro,Koga M.,Auwanit Wattana,Kilgore Paul Evan,Ariyoshi Koya,Sawanpanyalert Pathom
Epidemiology and Infection 141(9), 1840-1848, 2013-09
… A total of 755 highly active antiretroviral therapy (HAART)-naive HIV-infected patients were enrolled at a government hospital in Thailand from 1 June 2000 to 15 October 2002. … Of 700 (92·6%) patients with complete data, the prevalence of hepatitis B virus (HBV) surface antigen and anti-hepatitis C virus (HCV) antibody positivity was 11·9% and 3·3%, respectively. … Eight (9·6%) HBV co-infected patients did not have anti-HBV core antibody (anti-HBcAb). …
NAID 120005326901